secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncternal Therapeutics, Inc. (—)
CIK:        0001260990
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0000950170-24-002434
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncternal pre-announces $34.3M cash; 20:1 reverse stock split effective Jan 8
-----------------------------------------------------------------------------

- Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2023; subject to closing procedures.
- Shares outstanding: ~59.2M pre-split; ~3.0M post-split after 20:1 reverse stock split.
- Reverse stock split effective 12:01 a.m. ET on Jan 8, 2024; new CUSIP 68236P206.
- No fractional shares issued; fractional holders receive proportional cash payment.
- Exercise prices and share counts for stock options and warrants adjusted proportionally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/0000950170-24-002434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/onct-20240103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer